HOOKIPA to sell HB-400/HB-500 assets to Gilead for up to $10M; board approves dissolution

HOOKIPA Pharma Inc.

Gilead to acquire HB-400 and HB-500 assets for up to $10M in cash; $3M at closing, up to $7M in transfer completion payments.
Board approved dissolution of HOOKIPA; filing of Certificate of Dissolution expected after Transfer Plan completion.
Asset sale and dissolution require stockholder approval; proxy statement to be filed for special meeting.
CEO Malte Peters receives severance, accelerated equity vesting, and a Special Dissolution Success Bonus up to €482,591.
Collaboration Agreement and Stock Purchase Agreement with Gilead will terminate at closing.

item 1.01item 1.02item 5.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.